1207840-81-0

Basic information

• Product Name: tert-butyl 2-{1-[7-[4-(dimethylamino)-3-methylphenyl]-[1,6]naphthyridin-5-yl]-1H-pyrazol-4-yl}ethylcarbonate
• Synonyms: tert-butyl 2-{1-[7-[4-(dimethylamino)-3-methylphenyl]-[1,6]naphthyridin-5-yl]-1H-pyrazol-4-yl}ethylcarbonate
• CAS NO: 1207840-81-0
• Molecular Weight: 473.575
• Mol File: 1207840-81-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-{1-[7-[4-(dimethylamino)-3-methylphenyl]-[1,6]naphthyridin-5-yl]-1H-pyrazol-4-yl}ethylcarbonate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-{1-[7-[4-(dimethylamino)-3-methylphenyl]-[1,6]naphthyridin-5-yl]-1H-pyrazol-4-yl}ethylcarbonate(1207840-81-0)
• EPA Substance Registry System: tert-butyl 2-{1-[7-[4-(dimethylamino)-3-methylphenyl]-[1,6]naphthyridin-5-yl]-1H-pyrazol-4-yl}ethylcarbonate(1207840-81-0)

Safety Data

• Hazardous Substances Data: 1207840-81-0(Hazardous Substances Data)

Upstream product

• 180207-57-2 2-(1H-pyrazol-4-yl)ethan-1-ol 
• 1207840-78-5 7-(4-dimethylamino-3-methylphenyl)-[1,6]naphthyridin-5-ol 
• 143282-05-7 tert-butyl 4-(2-hydroxyethyl)-1H-pyrazole-1-carboxylate 
• 1207840-79-6 5-chloro-7-(4-dimethylamino-3-methylphenyl)-[1,6]naphthyridine 
• 60081-99-4 4-(Dimethylamino)-3-methylbenzonitrile 
• 185147-08-4 4-fluoro-3-methylbenzonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1207840-55-8 5-(4-(2-hydroxyethyl)pyrazol-1-yl)-7-(4-(dimethylamino)-3-methylphenyl)-[1,6]naphthyridine 

Relevant articles and documents

4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS

The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R1 can represent a group A selected from among the group comprising —O—R3, —NR3 R4, —CR3R4R5, -(ethyne)-R3, —S—R3, —SO—R3, and SO2—R3, or R1 represents a group B selected from among the group comprising: —C6-10-aryl;—a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom;—a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and—a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims 1, and R3,R4,R5,R6, and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.